Results 241 to 250 of about 693,900 (279)
Some of the next articles are maybe not open access.
2016
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifi cally and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the fi rst to therapeutically exploit mutant recessive cancer genes.
Grève, J.De +8 more
openaire +1 more source
Inhibition of Poly (ADP-ribose) polymerase 1 has relatively recently entered the clinic. The ground-breaking drug both scientifi cally and clinically was olaparib, but several other PARP inhibitors are in development. This treatment is the fi rst to therapeutically exploit mutant recessive cancer genes.
Grève, J.De +8 more
openaire +1 more source
PARP inhibitors for anticancer therapy
Biochemical Society Transactions, 2014PARP-1 [poly(ADP-ribose) polymerase-1], which plays a key role in DNA repair, was discovered 50 years ago. PARPi (PARP inhibitors), originally made to probe the function of the enzyme, inhibit DNA repair and increase the potency of anticancer cytotoxic agents.
openaire +3 more sources
A snapshot of chemoresistance to PARP inhibitors
Trends in Pharmacological Sciences, 2012The exploitation of synthetic lethality in BRCA-deficient tumor carriers using potent inhibitors of the enzyme poly(ADP-ribose) polymerase (PARP)-1 has led to an enthusiastic response among basic scientists, oncologists and pharmaceutical companies. However, accumulating evidence demonstrates that resistance to these drugs develops in tumors in both ...
openaire +3 more sources
Evolution of the Development of PARP Inhibitors
2023PARP inhibitors first entered the clinic in 2003 in combination with DNA damaging agents in an attempt to overcome treatment resistance to established agents. A brief overview of ADP-ribosylator enzyme biology and the early preclinical development of the class is discussed, illustrating the multiple biological activities of these enzymes and potential ...
openaire +2 more sources
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
Biomolecules, 2021Bart Cornelissen +2 more
exaly
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
Biomedicines, 2022Inés Rivero-Belenchon, Carmen Sáez
exaly
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors
European Journal of Cancer, 2022Julien Peron +2 more
exaly
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers
Biomedicines, 2021Niamh Lynam-Lennon +2 more
exaly